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Abstract 
Background: Human DNA topoisomerase II‑binding protein 1 (hTopBP1) plays an important role in DNA replica‑
tion and the DNA damage checkpoint pathway. The human mutY homolog (hMYH) is a base excision repair DNA 
glycosylase that excises adenines or 2‑hydroxyadenines that are mispaired with guanine or 7,8‑dihydro‑8‑oxoguanine 
(8‑oxoG). hTopBP1 and hMYH were involved in ATR‑mediated Chk1 activation, moreover, both of them were associ‑
ated with ATR and hRad9 which known as checkpoint‑involved proteins. Therefore, we investigated whether hTopBP1 
interacted with hMYH, and what the function of their interaction is.
Results: We documented the interaction between hTopBP1 and hMYH and showed that this interaction increased 
in a hydroxyurea‑dependent manner. We also mapped the hMYH‑interacting region of hTopBP1 (residues 444–991). 
In addition, we investigated several cell cycle‑related proteins and found that co‑knockdown of hTopBP1 and hMYH 
significantly diminished cell cycle arrest due to compromised checkpoint kinase 1 (Chk1) activation. Moreover, we 
observed that hMYH was essential for the accumulation of hTopBP1 on damaged DNA, where hTopBP1 interacts 
with hRad9, a component of the Rad9‑Hus1‑Rad1 complex. The accumulation of hTopBP1 on chromatin and its 
subsequent interaction with hRad9 lead to cell cycle arrest, a process mediated by Chk1 phosphorylation and ataxia 
telangiectasia and Rad3‑related protein (ATR) activation.
Conclusions: Our results suggested that hMYH is necessary for the accumulation of hTopBP1 to DNA damage lesion 
to induce the association of hTopBP1 with 9‑1‑1 and that the interaction between hMYH and hTopBP1 is essential for 
Chk1 activation. Therefore, we suggest that the interaction between hMYH and hTopBP1 is crucial for activation of the 
ATR‑mediated cell cycle checkpoint.
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Background
In response to DNA damage, eukaryotic cells initi-
ate checkpoint control mechanisms that help maintain 
genome integrity [1, 2]. The ataxia telangiectasia and 
Rad3-related protein (ATR) signaling cascade is an impor-
tant pathway involved in the checkpoint control mecha-
nism [3]. During ATR signaling in response to DNA 
damage, Rad17 forms a complex with 9-1-1 and loads onto 
stalled replication forks [4–9]. Subsequently, hTopBP1 
accumulates on replication protein A (RPA)-coated chro-
matin and is activated by interacting with hRad9 [4, 8, 10]. 
Then hTopBP1 interacts with ATR-ATRIP through its 
ATR-activating domain (AD) and stimulates ATR kinase 
activity [8, 9]. Activation of ATR phosphorylates a num-
ber of downstream proteins that coordinate the cell cycle 
checkpoint. Chk1 is one of the best-studied substrates 
of ATR [3]. ATR-activated Chk1 induces a transient cell 
cycle delay and arrest, which is followed by degradation 
of cell division cycle 25A (Cdc25A) and inhibition of cyc-
lin-dependent kinase (Cdk) [3, 8]. Consequently, Chk1 
activation initiates a reversible cell cycle arrest, a process 
considered essential for DNA repair [3].
Human DNA topoisomerase II-binding protein 1 
(TopBP1) and its orthologs play important roles in DNA 
replication and checkpoint control [1]. These proteins 
contain eight BRCA1 C-terminus (BRCT) domains, usu-
ally found in proteins that are involved in DNA repair 
and cell cycle checkpoint mechanisms [3, 11]. Through 
its interactions with other proteins via its BRCT domains, 
hTopBP1 performs diverse functions [1]. As part of the 
DNA damage response, hTopBP1 directly interacts with 
the ATR-ATRIP complex and activates ATR kinase [1, 
12]. hTopBP1 also interacts with the phosphorylated tail 
of Rad9 [1, 4]. Although binding to the ATR-ATRIP and 
9-1-1 complexes occurs independently, both are essential 
for ATR-mediated Chk1 phosphorylation [1, 4, 12]. Thus, 
hTopBP1 constitutes an important part of the ATR sign-
aling pathway and acts as a molecular bridge that associ-
ates the independently recruited 9-1-1 and ATR-ATRIP 
complexes, thereby leading to checkpoint activation [4].
One of the oxidative DNA lesions frequently gener-
ated upon exposure of cells to reactive oxygen species 
(ROS) is 7,8-dihydro-8-oxoguanine (8-oxoG) [13]. The 
presence of 8-oxoG on the replicating strand leads to fre-
quent misincorporation of adenine opposite a lesion, and 
results in G:C to T:A transversions after replication [13, 
14]. Human mutY homolog (MYH) is a DNA glycosylase 
involved in base excision repair (BER) [5, 13, 14]. This 
glycosylase initiates BER and reduces G:C to T:A muta-
tions by removing the adenine or 2-hydroxyadenines 
mispaired with guanine or 8-oxoG that arises through 
DNA replication errors [5, 13, 15, 16]. hMYH physically 
and functionally interacts with the 9-1-1 complex [14, 
16], and this interaction increases significantly following 
hydrogen peroxide treatment, implying that the associa-
tion primarily occurs for DNA repair [6]. In our previous 
study, we found that depletion of hMYH disrupts ATR 
and Chk1 activation following hydroxyurea (HU) and 
ultraviolet treatment [17]. In addition, we also observed 
endogenous interactions between hTopBP1 and hMYH 
as well as hRad9 and hMYH [5, 18]. These observations 
support the claim that hMYH is an important compo-
nent of the ATR signaling pathway. Importantly, cell 
cycle checkpoint proteins are recognized as key tumor 
suppressors, and their direct role in DNA repair, as with 
hMYH/9-1-1 interaction, can prevent the accumulation 
of mutations [19]. The connection between DNA repair 
and cell cycle checkpoints provides an additional mecha-
nism to preserve genomic integrity [19, 20].
Interestingly, a recent report suggested that an 
unknown factor caused the accumulation of hTopBP1 on 
damaged DNA, following the interaction between 9-1-1 
and hTopBP1 [8]. Based on our finding that hMYH inter-
acts with 9-1-1 and hTopBP1, we identified hMYH as 
the likely factor involved in ATR-mediated activation of 
Chk1. We further propose that during the DNA damage 
response, the association of hMYH with hTopBP1 is nec-
essary for the cell cycle arrest caused by ATR-mediated 
activation of Chk1. We also conclude that hMYH plays 
an important role in ATR signaling by interacting with 
9-1-1 and hTopBP1.
Results and discussion
hMYH physically interacts with hTopBP1
In our previous study, we observed that endogenous 
hMYH interacts with hTopBP1 [5]. Here, we examined 
whether exogenous hMYH interacted with hTopBP1 
using a co-IP assay. HEK293 cells were co-transfected 
with GST/c-Myc-hMYH or GST-hTopBP1/c-Myc-hMYH 
for 24 h. Then, the cell lysates were immunoprecipitated 
with an anti-GST antibody, and the precipitated lysates 
were analyzed by immunoblotting with anti-c-Myc and 
anti-GST antibodies. c-Myc-tagged hMYH was immu-
noprecipitated with GST-tagged hTopBP1, but not with 
GST (Fig.  1a). The association between hMYH and 
hTopBP1 was confirmed by co-IP with an anti-c-Myc in 
c-Myc/GST-hTopBP1- or c-Myc-hMYH/GST-hTopBP1-
co-transfected cells. We consistently found that GST-
tagged hTopBP1 interacted with c-Myc-tagged hMYH, 
but not with c-Myc (Fig. 1b). Based on our endogenous 
and exogenous interaction results, we performed GST 
pull-down assay to determine the physical interaction 
between hMYH and hTopBP1 (Fig.  1c). We prepared 
bacterially expressed and purified His-hMYH and GST-
hTopBP1. GST or GST-hTopBP1 was immobilized on 
glutathione Sepharose beads and mixed with purified 
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His-hMYH to pull-down. As we can see in upper panel, 
His-hMYH was pulled down by GST-hTopBP1, but not 
by GST alone. This result indicate that a direct interac-
tion between hMYH and hTopBP1. The above results 
demonstrated that hTopBP1 physically interacts with 
hMYH.
Effect of HU treatment on the interaction between hMYH 
and hTopBP1
HU is an inhibitor of ribonucleotide reductase that inhib-
its DNA replication in cells [18, 21, 22]. HU induces 
the accumulation of ROS and cell death. It also initiates 
cell cycle arrest, which in turn facilitates the interaction 
between hMYH and hTopBP1 [22–24]. Both hMYH and 
hTopBP1 are involved in DNA repair, and their expres-
sion increases following treatment with HU [1]. We 
examined the effect of HU treatment on the interaction 
between hTopBP1 and hMYH. HEK293 cells were either 
treated with HU or left untreated for various durations. 
After HU treatment, cells were immunoprecipitated with 
an anti-hTopBP1 antibody for immunoblotting. As shown 
in Fig. 2a (INPUT), the expression of both hTopBP1 and 
hMYH were increased by HU treatment. Quantifica-
tion of their expression (INPUT) confirmed that both 
hTopBP1 and hMYH were significantly increased by 
HU treatment (Fig.  2b, left panel). Moreover, the inter-
action between hTopBP1 and hMYH also increased in 
HU-treated cells in a time-dependent manner (Fig.  2a). 
Fig. 1 Interaction between hTopBP1 and hMYH. a HEK293 cells were co‑transfected with either GST and c‑Myc‑hMYH or GST‑hTopBP1 and c‑Myc‑
hMYH. Cell lysates were subjected to co‑immunoprecipitation (IP) and immunoblotting. Co‑IP was performed with an anti‑GST antibody and 
protein A/G PLUS‑agarose beads. Then, the precipitated proteins were immunoblotted (IB) with anti‑GST and anti‑c‑Myc antibodies. b Co‑IP was 
performed using an anti‑c‑Myc antibody in cells co‑transfected with either c‑Myc and GST‑hTopBP1 or c‑Myc‑hMYH and GST‑hTopBP1. The levels 
of the precipitated c‑Myc‑ and GST‑tagged proteins were assessed by immunoblotting. c Equal amount of purified His‑hMYH was mixed with GST 
or GST‑hTopBP1 bound glutathione Sepharose beads to pull down. Lane 1 purified His‑hMYH, lane 2 and 3 pull‑downs with GST or GST‑hTopBP1, 
respectively
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Quantification of the co-IP result confirmed that HU 
treatment significantly increased the interaction between 
hTopBP1 and hMYH (Fig. 2b, right panel).
We also imaged immunofluorescently stained cells 
in order to assess hTopBP1 and hMYH co-localization 
following HU treatment (Fig.  2c). HEK293 cells were 
prepared in coverglass bottom dishes and were either 
untreated (control; Ctr) or treated with 10 or 20  mM 
HU for 1 h. In untreated cells, hMYH was located in the 
cytoplasm and hTopBP1 was almost exclusively located 
in the nucleus (Fig.  2c). Therefore, no co-localization 
was observed. However, when we treated the cells with 
10 or 20  mM HU, hMYH expression is increased in 
nucleus, and we observed co-localization of hTopBP1 and 
hMYH (yellow in merge). Moreover, their co-localization 
increased in an HU dose-dependent manner. This result 
clearly indicated that the interaction between hMYH and 
hTopBP1 was significantly enhanced by HU in a time- 
and dose-dependent manner.
The BRCT 4–6 (D2) domain of hTopBP1 interacts with hMYH
To identify the region of hTopBP1 that associates with 
hMYH, we designed and generated several deletion 
mutants of hTopBP1 (Fig. 3a). Each deletion mutant was 
tagged with GST and co-transfected with c-Myc-tagged 
hMYH. Co-IPs were performed using an anti-c-Myc 
antibody. We observed that a construct corresponding to 
the D2 region of hTopBP1 (containing BRCT 4–6, amino 
acids 444–991) interacted with hMYH (Fig.  3b). This 
result clearly showed that residues 444–991 of hTopBP1 
were necessary for its interaction with hMYH.
Knockdown of hTopBP1 and hMYH affects cell cycle arrest
hTopBP1 and hMYH are required for the phosphoryla-
tion of Chk1, which is a checkpoint protein that induces 
cell cycle arrest following DNA damage [4, 17, 25]. 
Therefore, we hypothesized that interaction between 
hTopBP1 and hMYH would trigger the phosphorylation 
of Chk1. We knocked down the expression of hMYH 
and hTopBP1, either alone or together in the same cells, 
using siRNAs as indicated in Fig.  4a. siGFP-transfected 
cells were used as a control. Cells were treated with HU 
after transfection, and then protein levels were assessed 
by immunoblotting, which showed that hTopBP1 and 
hMYH were successfully knocked down by siRNA treat-
ment (Fig. 4a).
HU induces cell cycle arrest at the G1/S boundary by 
inhibiting ribonucleotide diphosphate reductase [24, 
26]. Therefore, we decided to investigate Chk1 phospho-
rylation at Ser 345 by assessing phospho-Chk1 (p-Chk1), 
an indicator of DNA damage, in HU-treated cells. As 
expected, a strong signal for p-Chk1 was observed in 
Fig. 2 The interaction between hTopBP1 and hMYH increases following HU treatment. a HEK293 cells were incubated with 20 mM HU for 1 or 3 h 
and then immunoprecipitated with anti‑hTopBP1 antibodies. The precipitated proteins were detected using anti‑hMYH and anti‑hTopBP1 antibod‑
ies. β‑Actin was used as a loading control. b Protein expression levels and their interaction were quantified and are presented as mean ± standard 
error (of three independent experiments). P values were calculated using a paired t test. *p < 0.05, **p < 0.01 compared to the Control (HU‑
untreated cells). c Cells were seeded and grown on coverglass bottom dishes. After 24 h, cells were either untreated or treated with various concen‑
trations of HU for 1 h, fixed with 4 % paraformaldehyde, and permeabilized with 0.1 % Triton X‑100 in PBS. Cells were subsequently incubated with 
anti‑hMYH and anti‑hTopBP1 antibodies and then stained with Alexa Fluor® 488 (hMYH/Green), Cy3 (hTopBP1/Orange), and To‑pro®‑3 (nucleus/Red). 
Scale bar 10 μm
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HU-treated siGFP-transfected cells (Fig.  4a). However, 
after knockdown of hTopBP1 or hMYH, Chk1 phos-
phorylation was significantly reduced in HU-treated 
cells (lane 5 versus lane 6, p  <  0.01; lane 5 versus lane 
7, p  <  0.05). Co-knockdown of hTopBP1 and hMYH 
(siTM) caused a greater reduction in Chk1 phosphoryla-
tion than that caused by a similar knockdown of siGFP, 
siMYH, or siTopBP1 alone (Fig. 4a, lane 5 versus lane 8, 
p  <  0.01). Quantification of the Chk1 phosphorylation 
in Fig. 4a (first panel of Fig. 4c) showed that knockdown 
of both hTopBP1 and hMYH synergistically reduced 
Chk1 phosphorylation. Hence, it is possible that the 
interaction between hMYH and hTopBP1 affects Chk1 
phosphorylation.
Next, we examined Cdk2 and Cdc25A to determine 
the effect of hMYH and hTopBP1 knockdown on sub-
strates downstream of phosphorylated Chk1 signaling. 
The phosphorylated, inactive form of Cdk2 (p-Cdk2, 
T14, Y15), which does not promote cell cycle progres-
sion, was higher in HU-treated siGFP-transfected cells 
(Fig. 4b). As expected, we observed a decrease in p-Cdk2 
levels in HU-treated siTopBP1-transfected and HU-
treated siMYH-transfected cells, compared with that 
in HU-treated siGFP-transfected cells (p  <  0.05). Simi-
larly, p-Cdk2 levels in the HU-treated co-knockdown 
cells were significantly lower than in the HU-treated 
siGFP-transfected cells (HU-siGFP versus HU-siTM, 
p  <  0.01). Additionally, degradation of Cdc25A, which 
is required for cell cycle arrest, was diminished in HU-
treated siTopBP1-transfected and HU-treated siMYH-
transfected cells compared to that in the HU-treated 
siGFP-transfected cells (p < 0.01). Moreover, HU-treated 
co-knockdown (hTopBP1 and hMYH) cells showed a 
remarkable defect in Cdc25A degradation (HU-siGFP 
versus HU-siTM, p < 0.001). The results shown in Fig. 4b 
(p-Cdk2 and Cdc25A levels) were quantitatively evalu-
ated (Fig. 4c). The results showed that depletion of both 
hMYH and hTopBP1 had a synergistic negative effect on 
cell cycle arrest in HU-treated cells through the dimin-
ishment of recovery of DNA damage (Fig. 4; Additional 
file 1).
hMYH is crucial for the association between hRad9 
and hTopBP1
After analyzing our data, we hypothesized that hMYH 
was likely to affect the activation of ATR signaling [5, 
17]. Therefore, we wanted to determine whether hMYH 
could affect the interaction between hRad9 and hTopBP1, 
an association that is necessary for inducing ATR acti-
vation. To determine the effect of hMYH, we depleted 
or overexpressed hMYH in HU-treated or untreated 
HEK293 cells and then conducted an IP assay using an 
anti-hRad9 antibody (Fig. 5). Figure 5a shows that knock-
down of hMYH induced a considerable decrease in the 
interaction between hRad9 and hTopBP1 compared to 
that in the control siGFP-transfected cells (p < 0.05). We 
also observed a significant decrease in the interaction 
between hTopBP1 and hRad9 in HU-treated siMYH-
transfected cells compared to that in HU-treated siGFP-
transfected cells. Similarly, we also studied the effect of 
overexpressing hMYH (Fig. 5b). The interaction between 
hRad9 and hTopBP1 was higher in cells overexpressing 
hMYH than in cells transfected with an empty expres-
sion vector (Fig. 5b, p < 0.05). These results suggest that 
hMYH is a critical factor involved in the interaction 
between hTopBP1 and hRad9, an important early step in 
ATR signaling. Moreover, it suggests that hMYH affects 
the interaction between hRad9 and hTopBP1 through its 
association with both hRad9 and hTopBP1.
hMYH required for accumulation of hTopBP1 to chromatin
Based on Fig.  5 results, we believed that hMYH affects 
chromatin association of hTopBP1. Therefore, we have 
investigated whether hMYH affects hTopBP1 accumula-
tion onto DNA lesion (Fig. 6). To examine whether chro-
matin association of hTopBP1 is mediated by hMYH, 
Fig. 3 Identification of the hMYH‑interacting domain of hTopBP1. 
a Schematic map of the hTopBP1 deletion mutants to identify the 
interacting region of hTopBP1. b Co‑IP and immunoblotting were 
performed on lysates expressing the various hTopBP1 deletion 
mutants. For the experiments, HEK293 cells were co‑transfected with 
full‑length c‑Myc‑hMYH and the various GST‑hTopBP1 mutants. Co‑IP 
was performed with an anti‑c‑Myc antibody, and the precipitated 
proteins were immunoblotted with anti‑GST and anti‑c‑Myc antibod‑
ies
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first we depleted hMYH using siRNA. HEK293 cells 
were transfected with siGFP or siMYH in HU treated or 
untreated cells, then chromatin isolation was performed. 
Chromatin associated proteins were collected and asso-
ciation were examined by western blotting. We observed 
that association of hMYH onto chromatin was dimin-
ished by siMYH treatment. As we expected, association 
of hTopBP1 onto chromatin was enhanced by HU treat-
ment, however, it was abolished by absence of hMYH. 
ORC2 was used for loading control of chromatin frac-
tions. This result indicates that hMYH and its interaction 
with hTopBP1 is important for accumulation of hTopBP1 
onto DNA lesion.
Conclusions
DNA damage checkpoints are surveillance mechanisms 
for preserving genome integrity and ensuring proper cel-
lular responses to stress [3, 14]. The ATR-Chk1 pathway 
is essential for this DNA damage checkpoint. ATR activa-
tion requires several factors, including Rad17-RFC, 9-1-1, 
hTopBP1, and ATRIP [9, 17, 27]. Based on our studies, we 
believe that hMYH is a component of the ATR signaling 
pathway and is required for Chk1 activation [5, 14]. 
Accordingly, in this study, we sought to elucidate the 
molecular mechanism underlying the accumulation of 
hTopBP1 at DNA damage sites. Additionally, we explored 
the interaction between hTopBP1 and hMYH and deline-
ated its role in DNA damage checkpoint signaling.
We studied the physical interaction between hTopBP1 
and hMYH (Fig. 1). Previous observations prompted us 
to examine whether HU-induced DNA damage could 
affect the interaction between hTopBP1 and hMYH 
[5, 17, 28]. Indeed, the expression levels of hMYH 
and hTopBP1 were increased following HU treatment 
(Fig. 2a, b). Additionally, the association between endog-
enous hTopBP1 and hMYH increased in a time-depend-
ent manner following HU treatment (Fig.  2a, b). In 
addition, hMYH and hTopBP1 co-localization increased 
in an HU dose-dependent manner (Fig. 2c). These results 
showed the interplay between hTopBP1 with hMYH 
related to the DNA damage response pathway. We also 
demonstrated that the D2 domain of hTopBP1 (residues 
444–991) was crucial for its interaction with hMYH 
(Fig. 3b).
Fig. 4 Knockdown of both hTopBP1 and hMYH affects cell cycle arrest. a HEK293 cells were either transfected with individual siRNAs targeted 
against GFP (siGFP), hMYH (siMYH), and hTopBP1 (siTopBP1) or co‑transfected with siTopBP1 and siMYH. Transfected cells were treated with 20 mM 
HU for 1 h. Total cell lysates were immunoblotted with anti‑hTopBP1, anti‑hMYH, anti‑Chk1, and anti‑phospho‑Chk1 antibodies. b The expression 
of hTopBP1, hMYH, or both was knocked down, following which the cells were incubated with 20 mM HU for 1 h. The cell lysates were analyzed 
by immunoblotting with anti‑p‑Cdk2 (T24, Y15) and anti‑Cdc25A antibodies. c The relative levels of p‑Chk1, Cdc25A, and p‑Cdk2 from replicate 
experiments were quantified and normalized to β‑actin, and the normalized data are presented as mean ± standard error (of three independent 
experiments). P values were calculated using a paired t test, *p < 0.05, **p < 0.01, ***p < 0.001
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Hahm et al., Yan et al., and Liu et al. performed experi-
ments in which either hMYH or hTopBP1 was depleted, 
and they observed inhibition of Chk1 phosphorylation in 
these cells [17, 29, 30]. Chk1 phosphorylation is necessary 
for the progression from cell cycle arrest to DNA repair 
[25, 31]. Interestingly, we observed that knockdown of 
both hMYH and hTopBP1 had a synergistic negative effect 
on cell cycle arrest following HU treatment (Fig.  4). Our 
observation indicates that the association between hMYH 
and hTopBP1 is probably required for inducing cell cycle 
arrest after DNA damage. Therefore, we suggest that this 
interaction is an important step in checkpoint signaling.
It has been reported that hTopBP1 has a key domain, 
AD, which is responsible for activating ATR [9, 27]. 
Fig. 5 hMYH is a key factor for the interaction between hTopBP1 and hRad9. a HEK293 cells transfected with siGFP or siMYH were either untreated 
or treated with 20 mM HU for 1 h. The cell lysates were subjected to IP with an anti‑hRad9 antibody. Immunoblotting was performed using the 
indicated antibodies. The bar graph shows the quantification of the interaction between hRad9 and hTopBP1. The values shown represent the 
mean ± standard error (of three independent experiments). b Cells overexpressing c‑Myc or c‑Myc‑hMYH were either untreated or treated 20 mM 
HU for 1 h. Then, an IP assay was performed with an anti‑hRad9 antibody. Immunoblotting was then performed as indicated. Quantification of the 
association between hRad9 and hTopBP1 is shown as mean ± standard error (of three independent experiments). P values were calculated using a 
paired t test, *p < 0.05
Fig. 6 Knockdown of hMYH affects chromatin association of hTopBP1. siGFP or siMYH transfected HEK293 cells were either untreated or treated 
with 20 mM HU for 1 h. The cells were lysed and chromatins were collected. Chromatin binding proteins were analyzed by western blotting. ORC2 
were used loading control. Quantification of the association of hTopBP1 with chromatin is shown as mean ± standard error (of three independent 
experiments). P values were calculated using a paired t test, **p < 0.01
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According to Delacroix et  al., when hRad9 interacts 
with hTopBP1, the AD domain of hTopBP1 and the 
phospho-Ser 387 of hRad9 are involved in Chk1 phos-
phorylation [4, 8, 32]. Interestingly, we observed that 
knockdown of hTopBP1 and hMYH affects Chk1 acti-
vation (Fig. 4a). Therefore, we decided to determine the 
role of hMYH in checkpoint signaling. As mentioned 
above, Lee et  al. pointed out that an unknown factor 
was required for the accumulation of hTopBP1 on the 
DNA lesion [8]. It was already known that hMYH is 
involved in the ATR-Chk1 pathway and that it interacts 
with 9-1-1, RPA, ATR, and hTopBP1, which are compo-
nents of the ATR-Chk1 pathway [17, 33, 34]. We first 
proposed that hMYH is the unknown factor involved in 
accumulation of hTopBP1 onto DNA lesion for induc-
ing the interaction between hRad9 and hTopBP1. Our 
results clearly demonstrated that chromatin associa-
tion of hTopBP1 is mediated by hMYH (Fig.  6), there-
fore, hMYH is indispensable for the interaction between 
hRad9 and hTopBP1 (Fig. 5).
Based on our findings, we suggested a model (Fig.  7). 
Following DNA damage, replication is initiated, and RPA 
binds to ssDNA. Then, hMYH and ATR-ATRIP associate 
with RPA, which is followed by Rad17/9-1-1 loading on 
the DNA lesion [8, 35]. hMYH then interacts with hRad9 
and ATR and induces the accumulation of hTopBP1 on 
DNA lesion [5]. Finally, hTopBP1 is activated through 
its interaction with Ser 387-phosphorylated hRad9 [4]. 
This association facilitates activation of ATR through 
the interaction between hTopBP1 and ATR-ATRIP [12, 
36]. An important feature of this model is that hMYH 
is involved in the recruitment of hTopBP1 to damaged 
DNA after 9-1-1 loading.
Taken together, our results indicated that hMYH is an 
important factor that recruits and accumulates hTopBP1 
on the DNA lesion, where it interacts with hRad9. This 
is an essential step in the process of Chk1 phosphoryla-
tion. In addition, we conclude that hTopBP1 and hMYH 
are important components of the ATR signaling pathway 
and suggest that their interaction is necessary for Chk1-
mediated cell cycle arrest.
Methods
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM; Wel-
gene, Daegu, South Korea), supplemented with 10 % fetal 
bovine serum (FBS; JR Scientific, Woodland, CA, USA) 
and 1  % penicillin–streptomycin solution (Welgene) at 
37 °C in a 5 % CO2 incubator. For transfection, cells were 
seeded (3 × 105–6 × 105 cells/mL) and transiently trans-
fected with Lipofectamine® 2000 (Invitrogen, Carlsbad, 
CA, USA), according to the manufacturer’s protocol. 
After incubating the cells for 24 h, 20 mM HU was added, 
and the cells were incubated for an additional 1 h.
siRNA construction
The siRNAs used to knockdown of endogenous hMYH 
and hTopBP1 were designed and purchased from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). An 
siRNA sequence corresponding to nucleotides 415–439 
of green fluorescent protein (GFP) was used as a nega-
tive control (Santa Cruz). hTopBP1 and hMYH knock-
down was performed according to the manufacturer’s 
instructions.
Chromatin fractionation
HEK293 cells were lysed with lysis buffer (10 mM HEPES 
pH 7.4, 10 mM KCl, 0.05 % NP-40), and nuclear extracts 
were lysed in Low salt buffer (10 mM Tris–HCl pH 7.4, 
0.2 mM MgCl2). Chromatins were collected by centrifu-
gation and chromatin binding proteins were disassoci-
ated from chromatin with 0.2 N HCl, and 1 M Tris–HCl 
pH 8.0 was added. Chromatin binding proteins were 
quantified using the Bio-Rad DC protein assay kit (Bio-
Rad, Hercules, CA, USA).
GST pull‑down assay
E. coli BL21 cells (Real Biotech Corporation, Ban-
qiao, Taipei, Taiwan) harboring the expression vectors 
Fig. 7 A model for the involvement of hMYH in ATR‑mediated check‑
point signaling. A model for the interaction of hMYH with hRad9 and 
hTopBP1 at stalled replication forks. See the “Conclusions” section for 
details
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(pGEX4T1/GST-hTopBP1, pET-28α/His-hMYH) were 
cultured and induced using isopropylthiogalactoside 
(IPTG, a final concentration of 0.5  mM) and incubated 
for 16 h at 18 °C. Cells were harvested and lysed by soni-
cation in lysis buffer [20 mM Tris–Cl (pH 7.5), 500 mM 
NaCl] together with protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA). After centrifugation, 5 mg/
ml of supernatant were pulled down by glutathione 
Sepharose 4B beads (GE Healthcare, UK) or Ni–NTA 
agarose resin (Qiagen, Valencia, CA, USA). Ni–NTA 
agarose beads bound His-hMYH protein were released 
from resin by elusion buffer [20  mM Tris–Cl (pH 7.4), 
500  mM NaCl] together with various concentration of 
Imidazole (50–300  mM). Equal concentration of puri-
fied His-hMYH (1.95  μg/μl) was then incubated with 
GST or GST-hTopBP1 in phosphate-buffered saline (PBS; 
Sigma-Aldrich), and proteins were incubated for 16 h at 
4 °C. After incubation, beads was washed with PBS then 
resuspended with reduced glutathione buffer [50  mM 
Tris–Cl (pH 8.0), 10 mM reduced glutathione]. Mixture 
of beads and reduced glutathione buffer were incubated 
for 15 min and centrifuged, then supernatants were col-
lected and analysed by western blot using His and GST 
antibody (Santa Cruz).
Western blot analysis
HEK293 cells were harvested and lysed with a lysis buffer 
[50 mM Tris–HCl (Bio Basic, Markham, Canada), 10 g/
mL PMSF, 100  mM NaCl, 5  mM EDTA, 1  % Nonidet 
P-40, and protease and phosphatase inhibitor cocktail 
(Sigma-Aldrich)] for 1  h at 4  °C. Protein extracts were 
collected after centrifugation, and proteins were quan-
tified. Protein samples were separated on an 8 or 12  % 
SDS-PAGE and transferred to polyvinylidene fluoride 
(PVDF) membranes (PALL Corporation, NY, USA). The 
membranes were blocked using 3  % non-fat dry milk 
(Bio Basic) in Tris-buffered saline with 0.05 % Tween 20 
(TBST) for 30 min. The membranes were then incubated 
with primary antibodies against hMYH (Abnova, Tai-
pei, Taiwan), hTopBP1 (Abcam, Cambridge, UK), hRad9 
(Bethyl Laboratories, Montgomery, TX, USA), c-Myc, 
GST, phospho-Chk1, Chk1, Cdc25A, phospho-Cdk2, 
Cdk2, and β-actin (Santa Cruz). After incubation with 
the primary antibodies, the membranes were incubated 
with the appropriate horseradish peroxidase (HRP)-con-
jugated secondary antibodies (Santa Cruz). Protein bands 
were detected with the ECL® Enhanced Chemilumines-
cence (ECL) analysis system (Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s 
protocol. The intensity of western blot bands was quan-
tified with Lab Works software (UVP Inc., Upland, CA, 
USA). Experiments were performed for three times 
and statistical analysis was conducted using student’s t 
test in Microsoft Excel for measuring the significance 
between the different values. Data were expressed as 
means ± standard errors and p < 0.05 (paired two-tailed 
t test, p  <  0.01, p  <  0.001) was considered statistically 
significant.
Immunoprecipitation
Total cell lysates were prepared from cells that were 
transiently transfected with different sets of expres-
sion vectors as described previously. Immunoprecipi-
tation (IP) was conducted by incubating the lysates 
with anti-c-Myc, anti-GST antibodies (as indicated) for 
1 h, and then adding protein A/G PLUS-agarose beads 
(Santa Cruz). Protein-bead complexes were pelleted 
by centrifugation and washed with PBS. The immu-
noprecipitated samples were analyzed by SDS-PAGE, 
and the immunoblot (IB) analysis was conducted with 
the indicated antibodies. To assess the endogenous 
hTopBP1-hMYH and hTopBP1-hRad9 interactions, 
IPs were conducted using the ImmunoCruz™ IP/WB 
Optima system (Santa Cruz). Beads were mixed with 
1  μg of anti-hTopBP1 or anti-hRad9 antibodies in 
PBS. Then, the mixture was incubated on a rotator at 
4  °C for 3 h. After incubation, the bead-antibody mix-
ture was washed in PBS three times. Cell lysates were 
quantified, mixed with the bead-antibody mixture, and 
rotated for 16 h at 4 °C. The mixture was washed with 
PBS three times and then mixed with 1× loading dye. 
Samples were boiled, and the supernatant was collected 
via centrifugation.
Immunofluorescence staining
HEK293 cells were seeded (1 × 105 cells/mL) on cover-
glass bottom dishes (SPL Life Sciences, Pocheon, South 
Korea), grown for 24  h, and then treated with various 
concentrations of HU for 1 h. Cells were fixed with 4 % 
paraformaldehyde in PBS for 20 min and permeabilized 
with 0.1 % Triton X-100 in PBS for 10 min. Blocking was 
performed with 15  % FBS in PBS for 15  min at 37  °C. 
Cells were incubated with the indicated primary antibod-
ies at 37 °C for 30 min, washed three times with PBS, and 
then incubated with Alexa Fluor® 488-conjugated anti-
mouse IgG (Invitrogen) and Cy3-conjugated anti-rab-
bit IgG (Sigma-Aldrich) for 30 min at 37  °C. Cells were 
washed three times with PBS, and the nucleus was coun-
terstained with To-Pro®-3 (Invitrogen). Finally, the cells 
were analyzed using a confocal fluorescence microscope 
(Olympus FV-1000; software, Olympus FluoView; Olym-
pus, Center Valley, PA, USA).
Plasmid construction
The hTopBP1 expression vector was constructed as 
follows: cDNA fragments harboring the D1 (amino 
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acids 1–444; BRCT 1–3), D2 (amino acids 444–991; 
BRCT 4–6), D3 (amino acids 991–1259; AD), and D4 
(amino acids 991–1486; AD and BRCT 7–8) regions of 
hTopBP1 were generated by PCR. The PCR products 
were digested with BamH1 and Not1 and subsequently 
ligated into a pEBG vector. The full-length hMYH con-
struct was generated using PCR. The PCR products 
were cleaved with EcoR1 and Sal1 and ligated into a 
pCMV-tag3A vector.
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